Data as of Q4 2025 (Dec 31, 2025)

DIADEMA PARTNERS LP

โ€ขCIK: 2026172โ€ขFiling: Q4 2025

**DIADEMA PARTNERS LP** manages $428M across a portfolio of 119 positions, exhibiting a concentrated, thematic approach. Top holdings reveal significant allocations to specialized sectors, notably XBI ($30.5M) and PRAX ($29.7M). The portfolio maintains deep exposure across key areas, with VKTX ($24.2M) and RNAM ($23.7M) anchoring substantial weightings. This structure suggests a focused, high-conviction mandate targeting specific market opportunities.

Total AUM
$131.4M
+ $296.6M in options
QoQ Performance
-3.1%
Positions
63
+ 56 options
Top 10 Concentration
47.0%
Latest Filing
Q4 2025

Top Holdings Allocation

XBI
PRAX
VKTX
RNAGBP
XBI7.1%
PRAX6.9%
VKTX5.7%
RNAGBP5.5%
NDQ4.3%
JAZZ4.2%
APGE3.7%
TERN3.3%

๐Ÿ“ˆ Biggest Buys

XBIPUT
SPDR SERIES TRUST
NEW
7.1% of portfolio
RNAGBPCALL
AVIDITY BIOSCIENCES INC
+993.3%
5.5% of portfolio
NDQPUT
INVESCO QQQ TR
NEW
4.3% of portfolio
JAZZCALL
JAZZ PHARMACEUTICALS PLC
+355.1%
4.2% of portfolio
JNJ
JOHNSON & JOHNSON
NEW
3.2% of portfolio

๐Ÿ“‰ Biggest Sells

REGNCALL
REGENERON PHARMACEUTICALS
-83.4%
0.9% of portfolio
PCVX
VAXCYTE INC
-89.5%
0.2% of portfolio
LLY
ELI LILLY & CO
-80.0%
0.5% of portfolio
QURE
UNIQURE NV
-85.0%
0.3% of portfolio
SLNOCALL
SOLENO THERAPEUTICS INC
-70.1%
0.6% of portfolio

Sector Breakdown

Other96.3%
Healthcare3.7%

๐Ÿšช Exited Positionssold since Q3 2025

SPY
SPDR S&P 500 ETF TR
SOLD
$13.3M
AGIO
AGIOS PHARMACEUTICALS INC
SOLD
$8.9M
BMY
BRISTOL-MYERS SQUIBB CO
SOLD
$5.9M
NBIX
NEUROCRINE BIOSCIENCES INC
SOLD
$5.3M
NKTR
NEKTAR THERAPEUTICS
SOLD
$4.3M
+28 more exited positions

Changes from Q3 2025

NEW46 new positions
โ†‘43 increased
โ†“28 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024